Tradestie Institutional Equity Comparison Engine

FBRX vs LYRA โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-08-26 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

FBRX Overall Edge

FBRX Captures Institutional Edge (3โ€“0 Pillars ยท 7โ€“0 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Forte Biosciences, Inc. Common Stock (FBRX) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, FBRX trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus LYRA at N/M Forward P/E and -25032.0% operating margin (-87.2% YoY). In options structure, FBRX sits in UNCLASSIFIED (3rd %ile IV; Dealer Gamma Walls on Pro) against LYRA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
FBRX N/M vs LYRA N/M Fwd P/E
Growth & Margin Winner FBRX
Op Margin 0.0% vs -25032.0% ยท YoY +0.0% vs -87.2%
Momentum & Technical Winner FBRX
1Y +580.4% vs -94.3% ยท 52W Pos 100% vs 1%
Options & Structure Winner FBRX
UNCLASSIFIED (3rd %ile IV) vs UNCLASSIFIED (N/A IV)
FBRX NASDAQ
Forte Biosciences, Inc. Common Stock
Pharmaceutical Preparations
$76.99
+0.03% 1D
Market Cap $1.6B
1M Return +0.44%
1Y Return +580.42%
Forward P/E N/M
Unified AI Score
52.7 / 100 HOLD
Tech 49.0 Fund 51.0 Flow 62.0 Mom 40.0
LYRA NASDAQ
Lyra Therapeutics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.49
-62.5% 1D
Market Cap $2.3M
1M Return -62.5%
1Y Return -94.34%
Forward P/E N/M
Unified AI Score
52.2 / 100 HOLD
Tech 60.0 Fund 56.0 Flow 50.0 Mom 59.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: FBRX +580.42% LYRA -94.34% Spread: +235.54 pp (FBRX Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period FBRX Revenue LYRA Revenue FBRX Op. Margin LYRA Op. Margin Margin Edge
FY2017 $0M N/A -91775.6% N/A FBRX
FY2018 $20M N/A -254.2% N/A FBRX
FY2019 $0M N/A -11288.9% N/A FBRX
FY2021 N/A $0M N/A -15303.5% LYRA
FY2022 N/A $0M N/A -4131.0% LYRA
FY2023 N/A $0M N/A -4308.1% LYRA
FY2024 N/A $0M N/A -6280.8% LYRA
FY2025 N/A $0M N/A -7794.5% LYRA

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: FBRX (7) vs LYRA (0)
Institutional Metric FBRX LYRA Criterion Row Winner
Market Capitalization Scale $1.6B $2.3M Larger Scale FBRX
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +0.0% -87.2% Higher Growth FBRX
Operating Margin (TTM) Profitability 0.0% -25032.0% Higher Margin FBRX
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -62.3% -404.5% Higher ROE FBRX
52-Week Range Position Momentum 100% ($10โ€“$77) 1% ($0โ€“$38) Stronger Trend FBRX
Beta / 30D Volatility Risk Regime 1.09ฮฒ ยท 3% Vol 0.33ฮฒ ยท 248% Vol Lower Realized Risk FBRX
Unified Institutional Score Composite Signal 52.7 / 100 (HOLD) 52.2 / 100 (HOLD) Higher Composite FBRX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full FBRX vs LYRA Buy Guide
FBRX UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 3rd %ile
IV Regime Compressed (<25th %ile)
Live FBRX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
LYRA UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live LYRA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither FBRX nor LYRA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.